Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results
- None.
- None.
Insights
Healthpeak Properties, Inc.'s report of a Net Debt to Adjusted EBITDAre ratio of 5.2x indicates a moderate level of leverage, which is within the acceptable range for real estate investment trusts (REITs). However, it is crucial to monitor this ratio as an increase could imply higher risk, particularly in a rising interest rate environment which could affect the cost of debt servicing. The issuance of $750 million in senior unsecured notes at a blended yield of approximately 5.35% reflects current market conditions and the company's creditworthiness. This capital raise, coupled with the disposal of non-core properties, suggests a strategic shift towards optimizing the portfolio for core operations and could impact the stock valuation positively if the funds are deployed effectively.
The total same-store portfolio cash NOI growth of 4.8% for the full year and 3.6% for the fourth quarter is a positive indicator of Healthpeak Properties' operational efficiency and asset quality. This growth rate is competitive within the healthcare real estate sector and demonstrates the company's ability to effectively manage its properties. The positive cash releasing spreads on renewals for both outpatient and lab leases, especially the notable +23% for lab leases, reflect strong demand in the life sciences sector and Healthpeak's ability to capitalize on this trend. These factors could lead to increased investor confidence and potentially enhance the company's market position.
The entitlements received for 1.3 million square feet of lab development and the commencement of new outpatient developments signal Healthpeak's proactive approach to growth within the healthcare real estate market. The strategic focus on lab and outpatient facilities is in line with broader industry trends towards specialized and decentralized healthcare services. The development completions and new starts reflect the company's commitment to expanding its portfolio in key life sciences clusters such as South San Francisco, which is known for its robust biotech ecosystem. These developments could potentially offer long-term value creation for shareholders through increased rental income and asset appreciation.
FOURTH QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
– Net income of
– Fourth quarter new and renewal lease executions totaled 1.1 million square feet:
- Outpatient Medical new and renewal lease executions totaled 743,000 square feet
- Lab new and renewal lease executions totaled 312,000 square feet
- Year-to-date 2024 Lab lease executions of 58,000 square feet with an additional 115,000 square feet under signed LOI
– Received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus in
– Commenced two on-campus outpatient developments in our HCA Healthcare ("HCA") development program
– Entered into a new
– Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended December 31, 2023
FULL-YEAR 2023 HIGHLIGHTS
– Net income of
– Portfolio leasing summary:
-
Full-year outpatient lease executions totaled 4.1 million square feet, with +
4% cash releasing spreads on renewals
-
Full-year lab lease executions totaled 985,000 square feet, with +
23% cash releasing spreads on renewals
– Development highlights:
- 2023 completions and new starts:
-
Nexus on Grand: Delivered the fully leased, 148,000 square foot,
$161 million South San Francisco
-
Vantage: Delivered the fully leased, 154,000 square foot,
$201 million South San Francisco
-
Callan Ridge: Completed core and shell work and delivered the space to the tenant for T.I. build out; the fully leased development in
Torrey Pines totals 185,000 square feet with an expected total development cost of$146 million
-
HCA Development Program: Commenced construction on two new outpatient developments totaling 192,000 square feet with total expected development costs of
$90 million
- Land bank and future developments:
- In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife where Healthpeak owns a total of 39 acres
- In December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus
– Issued
– Sold
– 2023 sustainability and responsible business recognitions include:
- Received a Green Star rating from the Global Real Estate Sustainability Benchmark (GRESB) and named a constituent in the FTSE4Good Index for the twelfth consecutive year
- Named to CDP's Leadership band for the eleventh consecutive year, named a constituent in the S&P Global Dow Jones Sustainability N. America Index for the eleventh consecutive year and World Index for the fourth time; and named to the S&P Global Sustainability Yearbook for the ninth consecutive year
- Named an ENERGY STAR Partner of the Year for the third time
- Named to Newsweek’s America’s Most Responsible Companies list for the fifth consecutive year
- Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by IR Magazine and Governance Intelligence
-
Certified a Great Place to Work for the fourth consecutive year; included in The Tennessean Top Workplaces for the second consecutive year; and a Middle
Tennessee Top Workplace for the first time
- Included in Fortune's Best Workplaces in Real Estate list for the second consecutive year
To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.
FOURTH QUARTER COMPARISON
|
Three Months Ended December 31, 2023 |
|
Three Months Ended December 31, 2022 |
||||||||
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||
Net income, diluted |
$ |
70,787 |
|
$ |
0.13 |
|
$ |
6,388 |
|
$ |
0.01 |
Nareit FFO, diluted |
|
263,810 |
|
|
0.48 |
|
|
192,158 |
|
|
0.35 |
FFO as Adjusted, diluted |
|
252,639 |
|
|
0.46 |
|
|
238,744 |
|
|
0.44 |
AFFO, diluted |
|
196,622 |
|
|
0.36 |
|
|
194,414 |
|
|
0.36 |
FULL-YEAR COMPARISON
|
Year Ended December 31, 2023 |
|
Year Ended December 31, 2022 |
||||||||
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||
Net income, diluted |
$ |
304,284 |
|
$ |
0.56 |
|
$ |
497,792 |
|
$ |
0.92 |
Nareit FFO, diluted |
|
994,574 |
|
|
1.79 |
|
|
904,573 |
|
|
1.66 |
FFO as Adjusted, diluted |
|
987,708 |
|
|
1.78 |
|
|
950,259 |
|
|
1.74 |
AFFO, diluted |
|
847,358 |
|
|
1.53 |
|
|
790,296 |
|
|
1.45 |
Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "December 31, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.
SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month and full-year SS Cash (Adjusted) NOI growth.
Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth |
||||||||||||
|
Three Month |
|
Full Year |
|||||||||
|
SS Growth % |
% of SS |
|
SS Growth % |
% of SS |
|||||||
Lab |
2.7 |
% |
47.1 |
% |
|
3.7 |
% |
46.6 |
% |
|||
Outpatient Medical |
4.3 |
% |
41.4 |
% |
|
3.4 |
% |
42.0 |
% |
|||
CCRC |
4.7 |
% |
11.5 |
% |
|
15.6 |
% |
11.5 |
% |
|||
Total Portfolio |
3.6 |
% |
100.0 |
% |
|
4.8 |
% |
100.0 |
% |
|||
CALLAN RIDGE LAB CAMPUS JOINT VENTURE SALE
As previously announced, in January 2024, Healthpeak formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a
The formation of the
Healthpeak began construction on the 185,000 square foot Callan Ridge campus in 2021. The two-building campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), through April 2035.
DEVELOPMENT UPDATES
VANTAGE ENTITLEMENTS
As previously announced, in December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab space at the Vantage campus, bringing the combined campus to approximately 1.7 million square feet upon full build out. The additional entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand.
Strategically located in the heart of
Healthpeak is
OUTPATIENT DEVELOPMENT PROGRAM WITH HCA
During the fourth quarter, Healthpeak added two on-campus outpatient developments with total expected development costs of
-
Galen Aurora: 72,000 square foot Class A medical training facility located on HCA’s Medical Center of Aurora hospital campus, a 325-bed acute care hospital in
Denver, CO where Healthpeak currently owns three on-campus buildings totaling approximately 165,000 square feet. HCA nursing and professional education affiliates have pre-leased100% of the development. -
McKinney Medical Center: 120,000 square foot Class A outpatient building on the campus of HCA's Medical City McKinney campus, a 281-bed acute care hospital in
McKinney, TX where Healthpeak currently owns two on-campus buildings totaling approximately 120,000 square feet. HCA affiliates have pre-leased approximately62% of the development for future outpatient services, including oncology, orthopedic, cardiology, wound care, imaging, and other services.
Since 2019, Healthpeak’s development program with HCA has delivered 9 outpatient buildings totaling 785,000 square feet with total development costs of approximately
MERGER WITH PHYSICIANS REALTY TRUST AND TERM LOAN UPDATE
As previously announced on October 30, 2023, Healthpeak and Physicians Realty Trust entered into a definitive agreement to combine in an all-stock merger of equals. Each company will hold its respective special meeting of stockholders on February 21, 2024. Subject to Physicians Realty Trust's stockholders approving the proposed merger and Healthpeak's stockholders approving the issuance of Healthpeak common stock in connection with the proposed merger, among other matters, as well as the satisfaction or waiver of customary closing conditions, the transaction is expected to close on March 1, 2024.
Additionally, Healthpeak expects to enter into a new
DIVIDEND
On January 31, 2024, Healthpeak's Board declared a quarterly common stock cash dividend of
2024 OUTLOOK
For full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger:
-
Diluted earnings per common share of
$0.07 $0.13
-
Diluted Nareit FFO per share of
$1.54 $1.60
-
Diluted FFO as Adjusted per share of
$1.73 $1.79
-
Diluted AFFO per share of
$1.50 $1.56
-
Total Portfolio Same-Store Cash (Adjusted) NOI growth of
2.25% –3.75%
This outlook assumes the merger with Physicians Realty Trust closes on March 1, 2024. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. Additionally, the outlook includes estimates for certain merger-related accounting adjustments, which will not be finalized until after the merger closes. For additional details and assumptions underlying this outlook, please see page 40 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for Friday, February 9, 2024, at 8:00 a.m. Mountain Time.
The conference call can be accessed in the following ways:
- Healthpeak’s website: https://ir.healthpeak.com/news-events
- Webcast: https://events.q4inc.com/attendee/292488797. Joining via webcast is recommended for those who will not be asking questions.
- Telephone: The participant dial-in number is (800) 715-9871.
An archive of the webcast will be available on Healthpeak's website through February 7, 2025, and a telephonic replay can be accessed through February 15, 2024, by dialing (800) 770-2030 and entering conference ID number 58822.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our proposed merger with Physicians Realty Trust; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Outlook." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the “Mergers”), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to
ADDITIONAL INFORMATION AND WHERE TO FIND IT
In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024.
STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION.
Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak’s website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust’s website at www.docreit.com.
PARTICIPANTS IN THE SOLICITATION
Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak’s stockholders and Physicians Realty Trust’s shareholders in respect of the proposed transaction. Information regarding Healthpeak’s directors and executive officers can be found in Healthpeak’s definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust’s trustees and executive officers can be found in Physicians Realty Trust’s definitive proxy statement filed with the SEC on March 23, 2023.
Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC’s website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above.
NO OFFER OR SOLICITATION
This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Healthpeak Properties, Inc. Consolidated Balance Sheets In thousands, except share and per share data |
|||||||
|
December 31,
|
|
December 31,
|
||||
Assets |
|
|
|
||||
Real estate: |
|
|
|
||||
Buildings and improvements |
$ |
13,329,464 |
|
|
$ |
12,784,078 |
|
Development costs and construction in progress |
|
643,217 |
|
|
|
760,355 |
|
Land and improvements |
|
2,647,633 |
|
|
|
2,667,188 |
|
Accumulated depreciation and amortization |
|
(3,591,951 |
) |
|
|
(3,188,138 |
) |
Net real estate |
|
13,028,363 |
|
|
|
13,023,483 |
|
Loans receivable, net of reserves of |
|
218,450 |
|
|
|
374,832 |
|
Investments in and advances to unconsolidated joint ventures |
|
782,853 |
|
|
|
706,677 |
|
Accounts receivable, net of allowance of |
|
55,820 |
|
|
|
53,436 |
|
Cash and cash equivalents |
|
117,635 |
|
|
|
72,032 |
|
Restricted cash |
|
51,388 |
|
|
|
54,802 |
|
Intangible assets, net |
|
314,156 |
|
|
|
418,061 |
|
Assets held for sale, net |
|
117,986 |
|
|
|
49,866 |
|
Right-of-use asset, net |
|
240,155 |
|
|
|
237,318 |
|
Other assets, net |
|
772,044 |
|
|
|
780,722 |
|
Total assets |
$ |
15,698,850 |
|
|
$ |
15,771,229 |
|
|
|
|
|
||||
Liabilities and Equity |
|
|
|
||||
Bank line of credit and commercial paper |
$ |
720,000 |
|
|
$ |
995,606 |
|
Term loans |
|
496,824 |
|
|
|
495,957 |
|
Senior unsecured notes |
|
5,403,378 |
|
|
|
4,659,451 |
|
Mortgage debt |
|
256,097 |
|
|
|
346,599 |
|
Intangible liabilities, net |
|
127,380 |
|
|
|
156,193 |
|
Liabilities related to assets held for sale, net |
|
729 |
|
|
|
4,070 |
|
Lease liability |
|
206,743 |
|
|
|
208,515 |
|
Accounts payable, accrued liabilities, and other liabilities |
|
657,196 |
|
|
|
772,485 |
|
Deferred revenue |
|
905,633 |
|
|
|
844,076 |
|
Total liabilities |
|
8,773,980 |
|
|
|
8,482,952 |
|
|
|
|
|
||||
Commitments and contingencies |
|
|
|
||||
|
|
|
|
||||
Redeemable noncontrolling interests |
|
48,828 |
|
|
|
105,679 |
|
|
|
|
|
||||
Common stock, |
|
547,156 |
|
|
|
546,642 |
|
Additional paid-in capital |
|
10,405,780 |
|
|
|
10,349,614 |
|
Cumulative dividends in excess of earnings |
|
(4,621,861 |
) |
|
|
(4,269,689 |
) |
Accumulated other comprehensive income (loss) |
|
19,371 |
|
|
|
28,134 |
|
Total stockholders’ equity |
|
6,350,446 |
|
|
|
6,654,701 |
|
|
|
|
|
||||
Joint venture partners |
|
310,998 |
|
|
|
327,721 |
|
Non-managing member unitholders |
|
214,598 |
|
|
|
200,176 |
|
Total noncontrolling interests |
|
525,596 |
|
|
|
527,897 |
|
|
|
|
|
||||
Total equity |
|
6,876,042 |
|
|
|
7,182,598 |
|
|
|
|
|
||||
Total liabilities and equity |
$ |
15,698,850 |
|
|
$ |
15,771,229 |
|
Healthpeak Properties, Inc. Consolidated Statements of Operations In thousands, except per share data |
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Revenues: |
|
|
|
|
|
||||||||||
Rental and related revenues |
$ |
412,332 |
|
|
$ |
392,245 |
|
|
$ |
1,631,805 |
|
|
$ |
1,541,775 |
|
Resident fees and services |
|
136,341 |
|
|
|
125,873 |
|
|
|
527,417 |
|
|
|
494,935 |
|
Interest income |
|
4,979 |
|
|
|
6,350 |
|
|
|
21,781 |
|
|
|
23,300 |
|
Income from direct financing leases |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,168 |
|
Total revenues |
|
553,652 |
|
|
|
524,468 |
|
|
|
2,181,003 |
|
|
|
2,061,178 |
|
|
|
|
|
|
|
|
|
||||||||
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
52,784 |
|
|
|
49,413 |
|
|
|
200,331 |
|
|
|
172,944 |
|
Depreciation and amortization |
|
188,544 |
|
|
|
179,157 |
|
|
|
749,901 |
|
|
|
710,569 |
|
Operating |
|
224,401 |
|
|
|
220,492 |
|
|
|
902,060 |
|
|
|
862,991 |
|
General and administrative |
|
21,556 |
|
|
|
57,872 |
|
|
|
95,132 |
|
|
|
131,033 |
|
Transaction and merger-related costs |
|
14,417 |
|
|
|
3,217 |
|
|
|
17,515 |
|
|
|
4,853 |
|
Impairments and loan loss reserves (recoveries), net |
|
(5,445 |
) |
|
|
3,326 |
|
|
|
(5,601 |
) |
|
|
7,004 |
|
Total costs and expenses |
|
496,257 |
|
|
|
513,477 |
|
|
|
1,959,338 |
|
|
|
1,889,394 |
|
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Gain (loss) on sales of real estate, net |
|
— |
|
|
|
(969 |
) |
|
|
86,463 |
|
|
|
9,078 |
|
Other income (expense), net |
|
2,600 |
|
|
|
(587 |
) |
|
|
6,808 |
|
|
|
326,268 |
|
Total other income (expense), net |
|
2,600 |
|
|
|
(1,556 |
) |
|
|
93,271 |
|
|
|
335,346 |
|
|
|
|
|
|
|
|
|
||||||||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |
|
59,995 |
|
|
|
9,435 |
|
|
|
314,936 |
|
|
|
507,130 |
|
Income tax benefit (expense) |
|
11,842 |
|
|
|
650 |
|
|
|
9,617 |
|
|
|
4,425 |
|
Equity income (loss) from unconsolidated joint ventures |
|
3,558 |
|
|
|
(156 |
) |
|
|
10,204 |
|
|
|
1,985 |
|
Income (loss) from continuing operations |
|
75,395 |
|
|
|
9,929 |
|
|
|
334,757 |
|
|
|
513,540 |
|
|
|
|
|
|
|
|
|
||||||||
Income (loss) from discontinued operations |
|
— |
|
|
|
873 |
|
|
|
— |
|
|
|
2,884 |
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) |
|
75,395 |
|
|
|
10,802 |
|
|
|
334,757 |
|
|
|
516,424 |
|
Noncontrolling interests’ share in continuing operations |
|
(4,451 |
) |
|
|
(4,274 |
) |
|
|
(28,748 |
) |
|
|
(15,975 |
) |
Net income (loss) attributable to Healthpeak Properties, Inc. |
|
70,944 |
|
|
|
6,528 |
|
|
|
306,009 |
|
|
|
500,449 |
|
Participating securities’ share in earnings |
|
(157 |
) |
|
|
(140 |
) |
|
|
(1,725 |
) |
|
|
(2,657 |
) |
Net income (loss) applicable to common shares |
$ |
70,787 |
|
|
$ |
6,388 |
|
|
$ |
304,284 |
|
|
$ |
497,792 |
|
|
|
|
|
|
|
|
|
||||||||
Basic earnings (loss) per common share: |
|
|
|
|
|
|
|
||||||||
Continuing operations |
$ |
0.13 |
|
|
$ |
0.01 |
|
|
$ |
0.56 |
|
|
$ |
0.92 |
|
Discontinued operations |
|
— |
|
|
|
0.00 |
|
|
|
— |
|
|
|
0.00 |
|
Net income (loss) applicable to common shares |
$ |
0.13 |
|
|
$ |
0.01 |
|
|
$ |
0.56 |
|
|
$ |
0.92 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per common share: |
|
|
|
|
|
|
|
||||||||
Continuing operations |
$ |
0.13 |
|
|
$ |
0.01 |
|
|
$ |
0.56 |
|
|
$ |
0.92 |
|
Discontinued operations |
|
— |
|
|
|
0.00 |
|
|
|
— |
|
|
|
0.00 |
|
Net income (loss) applicable to common shares |
$ |
0.13 |
|
|
$ |
0.01 |
|
|
$ |
0.56 |
|
|
$ |
0.92 |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
547,091 |
|
|
|
537,992 |
|
|
|
547,006 |
|
|
|
538,809 |
|
Diluted |
|
547,361 |
|
|
|
538,396 |
|
|
|
547,275 |
|
|
|
539,147 |
|
Healthpeak Properties, Inc. Funds From Operations In thousands, except per share data |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
Net income (loss) applicable to common shares |
|
$ |
70,787 |
|
|
$ |
6,388 |
|
|
$ |
304,284 |
|
|
$ |
497,792 |
|
Real estate related depreciation and amortization |
|
|
188,544 |
|
|
|
179,157 |
|
|
|
749,901 |
|
|
|
710,569 |
|
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures |
|
|
6,723 |
|
|
|
8,642 |
|
|
|
24,800 |
|
|
|
27,691 |
|
Noncontrolling interests’ share of real estate related depreciation and amortization |
|
|
(4,610 |
) |
|
|
(4,709 |
) |
|
|
(18,654 |
) |
|
|
(19,201 |
) |
Loss (gain) on sales of depreciable real estate, net |
|
|
— |
|
|
|
986 |
|
|
|
(86,463 |
) |
|
|
(10,422 |
) |
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures |
|
|
— |
|
|
|
45 |
|
|
|
— |
|
|
|
134 |
|
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net |
|
|
— |
|
|
|
— |
|
|
|
11,546 |
|
|
|
12 |
|
Loss (gain) upon change of control, net(1) |
|
|
— |
|
|
|
— |
|
|
|
(234 |
) |
|
|
(311,438 |
) |
Taxes associated with real estate dispositions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
29 |
|
Nareit FFO applicable to common shares |
|
|
261,444 |
|
|
|
190,509 |
|
|
|
985,180 |
|
|
|
895,166 |
|
Distributions on dilutive convertible units and other |
|
|
2,366 |
|
|
|
1,649 |
|
|
|
9,394 |
|
|
|
9,407 |
|
Diluted Nareit FFO applicable to common shares |
|
$ |
263,810 |
|
|
$ |
192,158 |
|
|
$ |
994,574 |
|
|
$ |
904,573 |
|
Diluted Nareit FFO per common share |
|
$ |
0.48 |
|
|
$ |
0.35 |
|
|
$ |
1.79 |
|
|
$ |
1.66 |
|
Weighted average shares outstanding - diluted Nareit FFO |
|
|
554,635 |
|
|
|
543,879 |
|
|
|
554,559 |
|
|
|
546,462 |
|
Impact of adjustments to Nareit FFO: |
|
|
|
|
|
|
|
|
||||||||
Transaction and merger-related items(2) |
|
$ |
10,842 |
|
|
$ |
3,215 |
|
|
$ |
13,835 |
|
|
$ |
4,788 |
|
Other impairments (recoveries) and other losses (gains), net(3) |
|
|
(4,407 |
) |
|
|
9,702 |
|
|
|
(3,850 |
) |
|
|
3,829 |
|
Restructuring and severance-related charges(4) |
|
|
— |
|
|
|
32,749 |
|
|
|
1,368 |
|
|
|
32,749 |
|
Casualty-related charges (recoveries), net(5) |
|
|
(3,424 |
) |
|
|
298 |
|
|
|
(4,033 |
) |
|
|
4,401 |
|
Recognition (reversal) of valuation allowance on deferred tax assets(6) |
|
|
(14,194 |
) |
|
|
— |
|
|
|
(14,194 |
) |
|
|
— |
|
Total adjustments |
|
|
(11,183 |
) |
|
|
45,964 |
|
|
|
(6,874 |
) |
|
|
45,767 |
|
FFO as Adjusted applicable to common shares |
|
|
250,261 |
|
|
|
236,473 |
|
|
|
978,306 |
|
|
|
940,933 |
|
Distributions on dilutive convertible units and other |
|
|
2,378 |
|
|
|
2,271 |
|
|
|
9,402 |
|
|
|
9,326 |
|
Diluted FFO as Adjusted applicable to common shares |
|
$ |
252,639 |
|
|
$ |
238,744 |
|
|
$ |
987,708 |
|
|
$ |
950,259 |
|
Diluted FFO as Adjusted per common share |
|
$ |
0.46 |
|
|
$ |
0.44 |
|
|
$ |
1.78 |
|
|
$ |
1.74 |
|
Weighted average shares outstanding - diluted FFO as Adjusted |
|
|
554,635 |
|
|
|
545,704 |
|
|
|
554,559 |
|
|
|
546,462 |
|
_______________________________________
(1) |
The year ended December 31, 2022 includes a gain upon change of control related to the sale of a |
|
(2) |
The three months and year ended December 31, 2023 include costs related to the proposed merger with Physicians Realty Trust, which are primarily comprised of legal, accounting, tax, and other costs that were incurred prior to year-end, partially offset by termination fee income associated with Graphite Bio, Inc., for which the lease terms have been modified to accelerate expiration of the lease to December 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations. |
|
(3) |
The three months and year ended December 31, 2022 include |
|
(4) |
The three months and year ended December 31, 2022 include |
|
(5) |
Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. |
|
(6) |
In conjunction with classifying the assets related to the Callan Ridge JV as held for sale as of December 31, 2023, we concluded it was more likely than not that we would realize the future value of certain deferred tax assets generated by the net operating losses of taxable REIT subsidiaries. Accordingly, during the three months and year ended December 31, 2023, we recognized the reversal of a portion of the associated valuation allowance and recognized a corresponding income tax benefit. |
Healthpeak Properties, Inc. Adjusted Funds From Operations In thousands |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
FFO as Adjusted applicable to common shares |
$ |
250,261 |
|
|
$ |
236,473 |
|
|
$ |
978,306 |
|
|
$ |
940,933 |
|
|
Stock-based compensation amortization expense |
|
3,513 |
|
|
|
1,903 |
|
|
|
14,480 |
|
|
|
16,537 |
|
|
Amortization of deferred financing costs |
|
3,088 |
|
|
|
2,812 |
|
|
|
11,916 |
|
|
|
10,881 |
|
|
Straight-line rents(1) |
|
(1,677 |
) |
|
|
(12,346 |
) |
|
|
(14,387 |
) |
|
|
(49,183 |
) |
|
AFFO capital expenditures |
|
(47,332 |
) |
|
|
(33,407 |
) |
|
|
(113,596 |
) |
|
|
(108,510 |
) |
|
Deferred income taxes |
|
117 |
|
|
|
(355 |
) |
|
|
(816 |
) |
|
|
(4,096 |
) |
|
Amortization of above (below) market lease intangibles, net |
|
(5,525 |
) |
|
|
(5,851 |
) |
|
|
(25,791 |
) |
|
|
(23,380 |
) |
|
Other AFFO adjustments |
|
(7,486 |
) |
|
|
3,536 |
|
|
|
(9,335 |
) |
|
|
520 |
|
|
AFFO applicable to common shares |
|
194,959 |
|
|
|
192,765 |
|
|
|
840,777 |
|
|
|
783,702 |
|
|
Distributions on dilutive convertible units and other |
|
1,663 |
|
|
|
1,649 |
|
|
|
6,581 |
|
|
|
6,594 |
|
|
Diluted AFFO applicable to common shares |
$ |
196,622 |
|
|
$ |
194,414 |
|
|
$ |
847,358 |
|
|
$ |
790,296 |
|
|
Diluted AFFO per common share |
$ |
0.36 |
|
|
$ |
0.36 |
|
|
$ |
1.53 |
|
|
$ |
1.45 |
|
|
Weighted average shares outstanding - diluted AFFO |
|
552,810 |
|
|
|
543,879 |
|
|
|
552,734 |
|
|
|
544,637 |
|
|
_______________________________________
(1) |
The year ended December 31, 2023 includes an |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208718917/en/
Andrew Johns, CFA
Senior Vice President – Investor Relations
720-428-5400
Source: Healthpeak Properties, Inc.
FAQ
What are the financial results for Healthpeak Properties, Inc. for the fourth quarter and full-year 2023?
What was the Total Same-Store Portfolio Cash NOI growth for Healthpeak Properties, Inc. in the fourth quarter and full-year 2023?
What were the lease executions for Healthpeak Properties, Inc. in the fourth quarter and full-year 2023?
What are the recent developments and joint ventures for Healthpeak Properties, Inc.?
What was the net debt to Adjusted EBITDAre ratio for Healthpeak Properties, Inc. in the fourth quarter 2023?
What were the 2023 sustainability recognitions for Healthpeak Properties, Inc.?
